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parametric data. OLS regression tested the relationship
between duration of therapy and presence of CHD risk
factors. RESULTS: For each statin, days on therapy dif-
fered significantly (p  0.001) by the number of risk fac-
tors. The number of CHD risk factors was positively sig-
nificant in predicting duration of therapy (p  0.0001) in
both new and continuing therapy. Duration of therapy
was associated with an increase of 48 days for each risk
factor for new patients and 58 days for continuing pa-
tients.CONCLUSIONS: Number of CHD risk factors is
positively correlated with length of therapy when using
statins as lipid lowering therapy for new and continuing
patients.
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INTRODUCTION: Naturalistic studies are essential to
prospectively study real-world antihypertensive treat-
ment OBJECTIVE: to evaluate the feasibility of perform-
ing a naturalistic study in newly diagnosed hypertensives
in terms of enrollment, adequacy, timeliness of data col-
lection, and study procedures. METHODS: CHOICE
prospectively collected actual practice data on the treat-
ment of newly-diagnosed hypertensive patients. Initial
therapy was randomly assigned to either Group 1 (beta
blockers or diuretics) or Group 2 (ACE inhibitors or cal-
cium channel blockers). The protocol made no demands
in scheduling visits or changing treatment during follow-
up. Physicians were blind to study purpose and hypothe-
ses. Only a final visit at 5  1 months, if none occurred
naturally, was mandated. Direct involvement of the
CHOICE study team was minimized using a Remote
Study Monitoring System to collect data and communi-
cate with study sites. RESULTS: Within 30 weeks, a total
of 55 physicians enrolled 512 patients with a mean age of
51 years and blood pressure of 158/99 mmHG. In all, 46
different antihypertensive medications were prescribed
and 2,554 office visits (range  1–16 visits per patient)
were attended. Other medical resource use was low dur-
ing the study period. A final, clean database was ready
for analysis 30 days after last patient last visit. CON-
CLUSIONS: It has been demonstrated that CHOICE is a
Statin Risk Factors (RF): 0 RF: 1 RF: 2 RF: 3 OR 4
Overall Median 305 431 481 550
atorvastatin 345 419 424 562
fluvastatin 289 428 505 568
pravastatin 303 444 469 533
feasible framework to study the real-world effectiveness
of initial therapy for newly diagnosed hypertension. Pro-
tocol flexibility and a novel electronic data entry system
are core elements of this naturalistic design.
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Spruill WJ, Wade WE, Leslie RB
University of Georgia College of Pharmacy, Athens, GA, USA
Economic analysis of various treatment modalities used
to prevent deep vein thrombosis (DVT) in various medi-
cal and surgical at-risk patients has been limited by lack
of consistent and representative methods to evaluate vari-
ous resource costs attributed to both the prevention of
DVT and the diagnosis and treatment of prophylaxis fail-
ures. OBJECTIVE: To develop a systematic and compre-
hensive method to identify and prioritize all direct costs
associated with DVT prophylaxis. METHODS: A deci-
sion tree was developed to identify and prioritize all med-
ical, surgical and diagnostic procedures that contribute to
overall direct cost. Included were costs of prophylaxis,
cost of diagnosing a prophylaxis failure (a DVT) and
costs of major complications of this therapy (pulmonary
embolism, major bleeding and thrombocytopenia.) Diag-
nostic procedures were also prioritized clinically as either
a “standard”, “alternative or confirmatory”, or “supple-
mental” procedure. This prioritization allows for proba-
bility multipliers to be assigned to each category of diag-
nostic procedures in order to get a weighted average of
the cost of this procedure. Likewise, the various costs as-
sociated with prophylaxis failure were prioritized. Next a
spreadsheet was developed to match this decision tree.
This spreadsheet contained all identified resource costs
shown on the decision tree and indicated the quantity or
units of each resource that are typically used. Lastly, the
corresponding CPT and ICD9 codes for all resources
were identified. RESULTS: Major categories of resources
identified include diagnostic, treatment, and monitoring.
These 3 areas are divided into 13 sub-categories which in
turn include over 60 specifically identified cost related re-
sources. CONCLUSION: This model allows any institu-
tion to accurately identify, prioritize and analyze institu-
tion specific resource costs instead of using literature
values to determine the cost-benefit of various pharma-
coprophylactic regimens including unfractionated hep-
arin and various low molecular weight heparins used at
their site.
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OBJECTIVE: To assess relative success rates and re-
source utilization differences between males and females
treated to NCEP and EAS cholesterol goals with HMG-
CoA reductase inhibitors. METHODS: In three open-
label clinical trials in the US and Europe, 998 patients (375
females and 623 males) with a CHD risk factor, docu-
mented CHD and/or PVD, were randomized to receive
one of five HMG-CoA reductase inhibitors (atorvastatin,
fluvastatin, lovastatin, pravastatin, or simvastatin). Phy-
sician visits occurred every 6 weeks and dose titrations
(either increased statin dose, or the addition of colestipol
or cholestyramine) were made every 12 weeks if target
LDL-C concentration levels were not achieved. The anal-
ysis takes a third party perspective by using insurance
payment rates for study medications, physician visits,
add-on therapies and treatments for adverse events, all
denominated in 1997 US dollars. RESULTS: NCEP or
EAS LDL-C targets were achieved with similar frequency
by males (75.7%) and females (74.7%). Accordingly, re-
source utilization was similar for males and females.
Mean total costs were similar for all males ($1529.94)
and females ($1470.99, p  0.776); males ($1280.62)
and females ($1252.95, p  0.665) reaching goal and
males ($2306.32) and females ($2115.59, p  0.103) not
reaching goal. Finally, mean total costs for males and fe-
males (and respective percentages achieving LDL-C tar-
gets) were similar among study medications: atorvastatin
$1044.49 (88.2%) and $1020.29 (90.7%); fluvastatin
$1815.03 (58.4%) and $1709.72 (55.5%); lovastatin
$2031.78 (77.9%) and $2045.43 (80.3%); pravastatin
$1878.90 (53.6%) and $1776.19 (35.7%) and simvasta-
tin $1475.48 (80.3%) and $1293.43 (77.0%). CON-
CLUSIONS: Successes in achieving LDL-C targets and
resource utilization were independent of gender. How-
ever the ability to reach target LDL-C, by use of specific
study medications, significantly impacts the total cost of
cholesterol reduction.
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CARE ORGANIZATION
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Considerable clinical trial data is available to support the
use of beta-blockers for the treatment of congestive heart
failure (CHF). OBJECTIVES: The primary objective is to
compare differences in health care costs (pharmacy, med-
ical, and total) between patients receiving carvedilol and
those not receiving a beta-blocker for the treatment of
CHF. The secondary objective is to determine differences
among cohorts with respect to CHF-related costs and
total health care costs (CHF and non-CHF related).
METHODS: Retrospective claims data from a large man-
aged care organization were analyzed. Patients were in-
cluded if they had an ICD-9 diagnosis code for CHF be-
tween 1/1/97 and 12/31/99, received an ACE inhibitor
and a diuretic, were continuously eligible, and at least 18
years old. The carvedilol group was newly started on
carvedilol and did not receive another beta-blocker. The
non beta-blocker group did not receive any beta-blockers
and had no contraindications to beta-blocker therapy. All
patients were followed for 1 year. Total health care costs
include costs for all services covered. CHF-related costs
include those directly related to the treatment of CHF.
RESULTS: There were a total of 9,439 patients, 52.3%
were female, and the average age was 77 (S.D.  9.5)
years. Total cost (CHF and non-CHF related) were mea-
sured after adjusting for age, gender, pre-total cost, and
Charlson Comorbidity Index. Patients in the carvedilol
group had higher pharmacy cost ($2,586 versus $1,343,
P  .0001), lower medical cost ($18,196 versus $22,168,
P  0.362), and lower total cost ($20,782 versus
$23,511, P  0.619). When measuring only CHF-related
costs, patients in the carvedilol group had higher phar-
macy cost ($1,489 versus $416, P  .0001), lower medi-
cal cost ($2,232 versus $3,105, P  0.450), and slightly
higher total cost ($3,721 versus $3,521, P  0.959).
CONCLUSION: The higher pharmacy cost of carvedilol
use appears to be offset by a reduction in total (CHF and
non-CHF related) medical cost.
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OBJECTIVE: To conduct a cost-effectiveness analysis of
tissue-Plasminogen Activator (t-PA) versus Streptokinase
(SK) for treating acute myocardial infarction (AMI). PER-
SPECTIVE: Societal. DATA SOURCES: The cost, clini-
cal outcomes and utilities were obtained from literature.
METHODS: Decision analytical model was used to eval-
uate the short and long-term outcomes and costs associ-
ated with the use of SK or t-PA for AMI. Clinical benefit
is expressed as Quality Adjusted Life Years (QALY) re-
sulting from the treatment. Patients presenting within six
hours after onset of symptoms, with a certain probability
of death may be treated with SK or t-PA. Survivors may
either get a disabling stroke or no stroke, patients with
no disabling stroke may or may not have a reinfarction.
Inpatient and long-term costs of coronary disease and
disabling stroke were included. Costs and QALYs were
discounted at 3%. Expected costs and QALYs yielded the
Incremental Cost-effectiveness Ratio (ICER). Sensitivity
analyses were performed on important factors. OUT-
COMES: QALY which incorporated 30 days mortality,
impacts of disabling stroke, reinfarction. Short-term and
